### Furosemide

**Section:** 16. Diuretics

**Status:** Essential medicine

**ATC codes:** C03CA01

**Indication:** Oedema

**INN:** Furosemide

**Medicine type:** Chemical agent

**List type:** Core

**Additional notes:** The square box applies only to the listing of furosemide on the EML.

**Formulations**

- **Parenteral > General injections > IV:** 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- **Oral > Liquid:** 20 mg per 5 mL (EMLc); 50 mg per 5 mL (EMLc)
- **Oral > Solid > tablet:** 40 mg; 20 mg

**EML status history**

- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 2007 (TRS 950)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives**

- bumetanide (ATC codes: C03CA02)
- torasemide (ATC codes: C03CA04)

**Patent information**

- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**

- [Furosemide](https://en.wikipedia.org/wiki/Furosemide)

**DrugBank**

- [Furosemide](https://www.drugbank.ca/drugs/DB00013)

---

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of furosemide (injection 10 mg/mL in 5 mL; tablet 20 mg (EML and EMLc); oral liquid 50 mg/5 mL (EMLc). The Committee also recommended the removal of furosemide 10 mg tablets from the EMLc.